EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa

Johanna Kuhlin iD, Jacob A M Stadler iD, Daniel J Grint iD, Richard Court iD, Graeme Meintjes iD, Nomfuneko Mtwa, Gary Maartens iD, Sean Wasserman iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag069 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Johanna Kuhlin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Rifampin, Antitubercular Agents, Tuberculosis, Multidrug-Resistant, Drug Monitoring. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Discovery Research Platform in Infection, Department of Science and Technology, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adherence to anti-tuberculosis (TB) therapy is an important determinant of treatment outcome in rifampicin-resistant tuberculosis (RR-TB). Understanding adherence to contemporary treatment regimens in routine care is needed to support implementation in TB programs. We aimed to characterize temporal adherence patterns among people receiving oral treatment for RR-TB.

Methods

We conducted a prospective observational cohort study at a referral TB hospital in South Africa. People aged ≥15 years with pulmonary RR-TB starting an oral 9- to 12-month regimen were included. Treatment adherence was measured using a digital pillbox during ambulatory care and with directly observed therapy during hospital care. The primary outcome was proportion of adherence days through 9 months. Latent class group-based trajectory modeling was used to identify temporal adherence patterns.

Results

Of 248 participants, 209 (84.3%) had assessable adherence data from the digital pillbox or directly observed therapy. Overall median adherence was 82% (interquartile range [IQR], 63%–98%) with combined measures, and 72% (IQR, 51%–92%) with digital pillbox only. Four distinct adherence patterns were identified. Adherence was 93%–100% in the first month. Two groups, representing 136 (65.1%) individuals, had small reductions in adherence over time, separated by higher and lower early adherence. In the other 2 groups, there was a 50% reduction in adherence by month 3 (48/209 [23.0%]) and month 6 (25/209 [12.0%]), respectively. Lower adherence over time was associated with having exclusive ambulatory care, treatment with the shorter regimen only, and age <40 years.

Conclusions

Treatment adherence declined over time in distinct temporal patterns. Group characteristics could identify individuals who may benefit from enhanced treatment support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinAntitubercular AgentsTuberculosis, Multidrug-ResistantDrug MonitoringMedication AdherenceHumansSouth AfricaFemaleAdultMaleProspective StudiesMiddle AgedAdministration, OralYoung AdultAdolescent

Stichwörter der Autor:innen

9- to 12-month regimenadherence trajectoriesdigital pillboxlatent class group-based trajectory modelingrisk factors

Substanzen

RifampinAntitubercular Agents

Autor:innen und Institutionen

  • Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Wellcome Discovery Research Platforms in Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Johanna Kuhlin, Jacob A M Stadler, Daniel J Grint, Richard Court, Graeme Meintjes, Gary Maartens, Sean Wasserman

Förderung

  • Wellcome Discovery Research Platform in Infection
  • Department of Science and Technology
  • Wellcome Trust
  • National Research Foundation
  • Swedish Heart and Lung Foundation
  • Gates Foundation
  • South African Medical Research Council
  • Swedish Society of Medicine

Zitieren

APA

Kuhlin, J., Stadler, J. A. M., Grint, D. J., Court, R., Meintjes, G., Mtwa, N., Maartens, G., & Wasserman, S. (2026). Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag069

Vancouver

Kuhlin J, Stadler JAM, Grint DJ, Court R, Meintjes G, Mtwa N, et al. Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag069

BibTeX
@article{Kuhlin2026,
  author = {Kuhlin, Johanna and Stadler, Jacob A M and Grint, Daniel J and Court, Richard and Meintjes, Graeme and Mtwa, Nomfuneko and Maartens, Gary and Wasserman, Sean},
  title = {Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag069}
}
Kostenlos starten →